4.7 Review

Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection

Journal

Publisher

MDPI
DOI: 10.3390/ijms22137170

Keywords

SGLT2 inhibitors; cardiac protection; autophagy; innate immunity

Funding

  1. National Health Research Institute [NHRI-EX106-10617SI, NHRI-110A1-CSCO-17212418]
  2. National Science Council [105-2628-B-182-009-MY4, 109-2314-B-182-070-MY3]
  3. Chang Gung Memorial Hospital [CMRPG3H0133, CMRPG3I0322, CMRPG3H0843, CORPG3K0011]

Ask authors/readers for more resources

SGLT2 inhibitors, a new class of anti-diabetic drugs, improve glycemic control and have the benefits of reducing blood pressure and body weight. Clinical studies have shown that SGLT2 inhibitors not only improve cardiovascular and renal outcomes, but also reduce hospitalization for heart failure.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin. This class of drugs has the advantages of no clinically relevant hypoglycemia and working in synergy when combined with currently available anti-diabetic drugs. While improving sugar level control in these patients, SGLT2 inhibitors also have the advantages of blood-pressure improvement and bodyweight reduction, with potential cardiac and renal protection. In randomized control trials for patients with diabetes, SGLT2 inhibitors not only improved cardiovascular and renal outcomes, but also hospitalization for heart failure, with this effect extending to those without diabetes mellitus. Recently, dynamic communication between autophagy and the innate immune system with Beclin 1-TLR9-SIRT3 complexes in response to SGLT2 inhibitors that may serve as a potential treatment strategy for heart failure was discovered. In this review, the background molecular pathways leading to the clinical benefits are examined in this new class of anti-diabetic drugs, the SGLT2 inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available